Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).
Unlock the market timeline & signal feed
26 signals in the last 90 days.
The order this company entered each market — oldest to newest
Project Manager, R&D
Telix Completes IPAX-2 Glioblastoma Trial Enrollment
Sign up to see the full signal feed
How Telix Pharmaceuticals Limited's international expansion compares to its competitors
Telix Pharmaceuticals LimitedYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Telix Pharmaceuticals LimitedYou | 7 | 0 | -76% | 26 | 81 |
Senior Director, Global Security and Resiliency
View postingUnited States · 2d ago
Global Clinical Lead
View postingUnited Kingdom · last wk.
Manufacturing Process & Operations Engineer
View postingLiège, Walloon Region, Belgium · last wk.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Telix Pharmaceuticals achieved its FY 2025 revenue guidance of US$804M (A$1.2B) and is accelerating growth with the launch of Gozellix.
Telix Pharmaceuticals has dosed the first patient in a Phase 3 study of TLX591-Px for prostate cancer imaging in Japan, aiming to support future marketing authorization.
Telix Pharmaceuticals begins Phase III trial of TLX591-Px for prostate cancer imaging in Japan, aiming for future regulatory approval.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Telix Pharmaceuticals Limited's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
